Evidence map›Paper›PMID 41550634›Full record

ReviewPharmaceutical science advances2025

Artificial intelligence in human immunodeficiency virus mutation prediction and drug design: Advancing personalized treatment and prevention.

Karamot O Oyediran, Peace-Ofonabasi O Bassey, Deborah A Ogundemuren, Abdullahi Abdulraheem, Chukwuemeka P Azubuike, Andrew N Amenaghawon, Margaret O Ilomunaya

Abstract readReview
In one paragraph

Review in Pharmaceutical science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Anti-HIV Potential ofViruses · 2026
    Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Karamot O OyediranDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.
Peace-Ofonabasi O BasseyDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.
Deborah A OgundemurenDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.
Abdullahi AbdulraheemDepartment of Pharmacognosy, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.
Chukwuemeka P AzubuikeDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.
Andrew N AmenaghawonDepartment of Chemical Engineering, Faculty of Engineering, University of Benin, Benin City, Nigeria.
Margaret O IlomunayaDepartment of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, University of Lagos, Surulere, Lagos, PMB 12003, Nigeria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant advancements in highly active antiretroviral therapy (HAART), Human Immunodeficiency Virus (HIV) remains a global health challenge due to its high mutation rate, drug resistance, and the complexity of treatment optimization. Artificial intelligence (AI) has emerged as a transformative tool in HIV research, offering innovative solutions for predicting viral mutations, optimizing drug discovery and formulation design. However, challenges such as limited access to diverse datasets, ethical concerns, and model interpretability hinder the full potential of AI in HIV research. This review highlights gaps in AI-driven HIV research and explores advancements to address these challenges. AI-driven platforms, such as DeepHIV and geno2pheno, have demonstrated success in forecasting resistance mutations and guiding therapeutic decisions. AI is also revolutionizing drug formulation development by enhancing solubility, bioavailability, and stability, while improving patient adherence through advanced delivery systems. Current applications of AI in HIV mutation prediction, drug discovery, and formulation optimization have highlighted the potential of AI towards HIV management and eradication while addressing gaps in data availability and model transparency. By integrating structural, pharmacological, and clinical data, AI provides a comprehensive framework for rational drug design and personalized treatment strategies. By leveraging AI-driven insights, HIV treatment and prevention can become more personalized, efficient, and sustainable. Future research should focus on overcoming data limitations, enhancing model interpretability, and exploring innovative AI approaches to contribute to the global fight against the HIV epidemic.

Indexed as

Artificial intelligenceDrug resistanceFormulation optimizationHIV viral mutationPersonalized treatment

Identifiers

PMID41550634
PMCPMC12710026

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.